Overview

Phase I Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer

Status:
RECRUITING

Trial end date:
2028-09-01

Target enrollment:

Participant gender:

Summary

This study is a multicenter, open label phase I clinical trial aimed at evaluating the pharmacokinetics, tolerability, safety and immunogenicity of SHR-1316 (sc) subcutaneous administration combined with carboplatin and etoposide as first-line treatment for extensive stage small cell lung cancer, and to observe the initial anti-tumor efficacy.

Phase:

PHASE1

Details

Lead Sponsor:

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Treatments:

Carboplatin
Etoposide
Injections